title: Prognostic value of serial cardiac assessment and familial screening in patients with dilated cardiomyopathy.
abstract: OBJECTIVE
  This prospective study was performed to analyse whether routine clinical follow-up investigations at 12+/-6 months add to risk stratification and improve survival rates in patients with a first diagnosis of dilated cardiomyopathy (DCM).
  
  
  METHODS
  Four hundred and eighty consecutive patients (mean age 53.4+/-12.3 years, 369 males, mean NYHA class 2.4+/-0.8) with invasively confirmed DCM were included and followed for 3.9+/-3.5 years. Patients were requested to adhere to a follow up investigation within 6-18 months either at the referring physicians or at our out patient department. Two hundred and eighty-one of the 480 patients presented for follow up which consisted of a detailed evaluation of symptoms, standardized physical examination, 12-lead-electrocardiogram recording and echocardiography. Seventeen patients were lost for follow up, 182 did not seek specialized medical follow up. Patients outcome was assessed by structured telephone interviews.
  
  
  RESULTS
  Independent predictors of death or transplantation at initial diagnosis were LV-ejection fraction <30% (P=0.0001, risk ratio 2.25), LV-end diastolic pressure >or=15 mmHg (P=0.002, risk ratio 2.0), age >or=54 years, (P=0.04, risk ratio 1.55), and presence of left bundle branch block (P=0.046, risk ratio 1.53). On follow up investigations only deterioration of clinical status by at least one NYHA-class (P=0.001, risk ratio 2.6) and new onset or worsening of mitral regurgitation (P=0.02, risk ratio 1.8), remained independent prognostic factors for cardiac death. Patients who presented for routine follow up revealed significant better 5-year survival rates (n=281, 70%) than those who did not (n=153, 55%, P=0.005).
  
  
  CONCLUSIONS
  Routine clinical follow up investigations within 6-18 months after first diagnosis of DCM adds to risk stratification and improves survival rates.
authors.affiliation: Medizinische Klinik III, University of Heidelberg, 69115 Heidelberg, Germany. ekkehard_gruenig@med.uni-heidelberg.de
authors.forename: Ekkehard
authors.initials: E
authors.lastname: Grünig
authors.forename: Andreas
authors.initials: A
authors.lastname: Benz
authors.forename: Derliz
authors.initials: D
authors.lastname: Mereles
authors.forename: Kristina
authors.initials: K
authors.lastname: Unnebrink
authors.forename: Helmut
authors.initials: H
authors.lastname: Kücherer
authors.forename: Markus
authors.initials: M
authors.lastname: Haass
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Kübler
authors.forename: Hugo A
authors.initials: HA
authors.lastname: Katus
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D006348:Cardiac Surgical Procedures; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy; D004311:Double-Blind Method; D004562:Electrocardiography; D005192:Family Health; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010349:Patient Compliance; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D011669:Pulmonary Wedge Pressure / Q000502:physiology; D013318:Stroke Volume / Q000502:physiology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors